Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press22110.17650/1726-9776-2011-7-4-54-59PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫANALYSIS OF COMPLICATIONS DUE TO INTRATISSUE RADIOTHERAPY USING CONSTANT SOURCES IN PATIENTS WITH PROSTATE CANCERАНАЛИЗ ОСЛОЖНЕНИЙ ВНУТРИТКАНЕВОЙ ЛУЧЕВОЙ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ПОСТОЯННЫХ ИСТОЧНИКОВ У БОЛЬНЫХ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫPetrovskyA. V.ПетровскийА. В.
Russian Federation
alexpetrovsky@hotmail.comBukharkinB. V.БухаркинБ. В.
Russian Federation
alexpetrovsky@hotmail.comSholokhovV. N.ШолоховВ. Н.
Russian Federation
alexpetrovsky@hotmail.comRoshchinD. A.РощинД. А.
Russian Federation
alexpetrovsky@hotmail.comMatveyevV. B.МатвеевВ. Б.
Russian Federation
alexpetrovsky@hotmail.comNechushkinM. I.НечушкинМ. И.
Russian Federation
alexpetrovsky@hotmail.comN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ РОНЦ им. Н.Н. Блохина РАМН, Москва301220117454590208201402082014https://oncourology.abvpress.ru/oncur/article/view/221

Brachytherapy is a standard treatment for localized advanced prostate cancer (PC). Complications due to interstitial radiotherapy using permanent sources were analyzed in 149 patients. The incidence of early grade 3 radiation urethritis was 7.4 % and that of rectitis was 3.4%. Late radiation urethritis and rectitis were recorded in 3.4 and 0.7 %, respectively. Sexual function 12 months later was preserved in 86.6 % of the patients. Studies established no statistically significant factors that influenced the frequency of complications. The patients with a prostate volume of > 50 cm3, a preoperative international prostate symptom score of > 15, a urine flow rate of < 15 ml/min, and urethral andrectal radiation doses of > 210 and > 180 Gy, respectively, tended to have more common radiation reactions. Thus, brachytherapy is a reasonably safe treatment for PC.

Брахитерапия — стандартный метод лечения локализованного рака предстательной железы (РПЖ). Нами проведен анализ осложнений внутритканевой лучевой терапии с использованием постоянных источников у 149 пациентов. Частота ранних лучевых уретритов III степени составила 7,4 %, ректитов — 3,4 %. Поздние лучевые уретриты зафиксированы в 3,4 % случаев, ректиты — в 0,7 %. Половая функция через 12 мес сохранена у 86,6 % пациентов. По результатам исследования статистически значимых факторов, влияющих на частоту осложнений, не установлено. Выявлена тенденция к более частым лучевым реакциям у пациентов с объемом предстательной железы > 50 см3, предоперационной оценкой IPSS (International prostate symptoms score) > 15, скоростью мочеиспускания < 15 мл/мин, дозой облучения уретры > 210 Гр и прямой кишки > 180 Гр. Таким образом, брахитерапия представляется достаточно безопасным методом лечения РПЖ.

prostate cancerbrachytherapycomplicationsрак предстательной железыбрахитерапияосложнения1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ. Вестн РОНЦ им Н.Н. Блохина РАМН 2009;20(3) (прил. 1).Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ. Вестн РОНЦ им Н.Н. Блохина РАМН 2009;20(3) (прил. 1).2. Choe K.S., Liauw S.L. Radiotherapeutic strategies in the management of low-risk prostate cancer. The Scientific World Journal 2010;10:1854−69.Choe K.S., Liauw S.L. Radiotherapeutic strategies in the management of low-risk prostate cancer. The Scientific World Journal 2010;10:1854−69.3. Ciezki J.P., Klein E.A. Brachytherapy or surgery? A composite review. Oncology (Williston Park) 2009;23: 960−4.Ciezki J.P., Klein E.A. Brachytherapy or surgery? A composite review. Oncology (Williston Park) 2009;23: 960−4.4. Pieters B.R., de Back D.Z., Koning C.C., Zwinderman A.H. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiotherapy and Oncology 2009;93:168−73.Pieters B.R., de Back D.Z., Koning C.C., Zwinderman A.H. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiotherapy and Oncology 2009;93:168−73.5. Klein E.A., Ciezki J., Kupelian P.A., Mahadevan A. Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol2009; 27: 67−71.Klein E.A., Ciezki J., Kupelian P.A., Mahadevan A. Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol2009; 27: 67−71.6. Blasko J.C., Ragde H., Grimm P.D. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol 1991; 137(Suppl):113–8.Blasko J.C., Ragde H., Grimm P.D. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol 1991; 137(Suppl):113–8.7. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995;32:465–71.Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995;32:465–71.8. Marcus D.M., Jani A.B., Godette K., Rossi P.J. A review of low-dose-rate prostate brachytherapy techniques and outcome .Marcus D.M., Jani A.B., Godette K., Rossi P.J. A review of low-dose-rate prostate brachytherapy techniques and outcome .J Nat Med Assoc 2010; 102:500−10.9. Phan J., Swanson D.A., Levy L.B. et al. Late complications after prostate brachytherapy for localized prostate cancer: incidence and management. Cancer 2009; 115:1827−39.Phan J., Swanson D.A., Levy L.B. et al. Late complications after prostate brachytherapy for localized prostate cancer: incidence and management. Cancer 2009; 115:1827−39.